CD19 and lymphoma: To date, most chimeric antigen receptor (CAR)-T cell products approved by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for second-line immunotherapy in lymphomas and/or leukemias target the B-cell antigen CD19.